Introduction {#sec1-1}
============

Cervical cancer has a high incidence and mortality rate and is the second most common cancer among women worldwide. About 200,000 women in developing countries died of this disease in 2010, and 46,000 of them were aged 15-49 years (Forouzanfar et al., 2014; Nindrea et al., 2018).

Cervical cancer is caused by a long-term infection of Human Papillomavirus (HPV). DNA viruses merge with human DNA resulting in an increased expression of E6 and E7 proteins, and subsequently interact with the oncogenic proteins and interfere with the cell cycle (Steben and Duarte-Franco, 2007). Protein E6 inhibits the tumor suppressor gene of p53 by increasing its proteasomal degradation. p53 is a tumor suppressor gene that acts as a transcription factor in regulating the transcription process of hundreds of genes encoding proteins for protection and maintaining genome integrity. It induces cell cycle arrest and DNA repair in the event of DNA damage, and triggers apoptosis when DNA repair is unsuccessful (Kumari et al., 2014).

Inactivation of p53 will cause down-regulation of miR-34a expression, since miR-34a is a direct target of transcriptional p53 transcription factor. Transactivation of expression of miR-34a is triggered by the p53 bond at the binding site of the promoter region miR-34a. Cells with decreased miR-34a expression showed rapid cell growth and avoided apoptosis. The mechanism of this process involves several components in the cell cycle including CDK4, cyclin E2, E2F-1, MET hepatocyte growth factor and Bcl-2 (Bommer et al., 2007; Feng et al., 2011;Hermeking, 2010).

Human Papillomavirus 16/18 E6 oncoproteins are highly expressed in tumors and associated with Tissue Inhibitor of Metalloproteinases-3 (TIMP-3) inactivation. TIMP-3 is important for limiting inflammation, so the loss of TIMP-3 will induce chronic inflammation and may promote the formation of malignancies, resulting in poor survival and relapse in lung cancer patients infected with HPV. Loss of TIMP-3 activity was found to increase IL-6 production via TNF beta pathways, thus increasing tumor malignancy and resulting in relapse and poor survival in HPV-positive lung cancer patients (Wu et al., 2012).

After undergoing primary treatments both surgery and radiation, 40% of cervical cancer patients still have residual tumors, distant metastasis and/or relapse (Minig et al., 2014). Chemotherapeutic drugs such as cisplatin (CIS) have many side effects, including nephrotoxicity, bone marrow suppression, neurotoxicity, and vomiting (Kilic et al., 2014; Kitagawa et al., 2015). Doxorubicin (DOX), an anthracycline antibiotic is one of the chemotherapies for the treatment of some cancers. The antitumor activity of DOX is mainly due to the DNA damage caused by inhibition of DNA topoisomerase II, and its side effects are cardiotoxicity and resistance (Park et al., 2014). Less optimal treatment of cervical cancer and side effects encourage researchers to look for the more effective and selective cancer drugs or for a combination of chemotherapeutic drugs (co-chemotherapy).

The co-chemotherapy approach is one of the alternative methods for solving drug resistance problems, and increases efficacy and allows the use of drug's lower doses to reduce side effects (Chou, 2010). The compound of 1,2-epoxy-3(3-(3,4-dimethoxyphenyl)-4H-1-benzopyran-4-on) propane (EPI) obtained from clove leaf oil (eugenol) is widely available in Indonesia. Its structure is similar to genistein, an isoflavone found in soybeans (Nurung et al., 2016). According to our knowledge, this is the first research about the anticancer and co-chemotherapy effects of EPI compounds on cultures of cervical cancer. The aim of this study was to observe the anticancer mechanism of EPI and its combination with DOX and CIS, and their effect on miR-34a, p53, and TIMP-3 as molecular targets.

Materials and Methods {#sec1-2}
=====================

This study was a randomized post-test only control group design in vitro experimental research. The HeLa cells were randomly divide into 8 groups, with Group 1 (negative control), 2 (was given EPI ½ IC~50~), 3 (was given EPI IC~50~), 4 (was given EPI 2IC~50~), 5 (was given DOX IC~50~), G6 (was given EPI ½ IC~50~ + DOX ½IC~50~), 7 (was given IC~50~ CIS), and 8 (was given EPI ½ IC~50~ + CIS ½IC~50~). The EPI compound was synthesized at the Faculty of Mathematics and Natural Sciences of Universitas Gadjah Mada by Dr. Andi Hairil Alimuddin. HeLa cells obtained from Parasitology Laboratory, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Indonesia. The cells were grown using RPMI (Gibco), supplemented with 10% Fetal Bovine Serum (FBS Qualified, Gibco, Invitrogen USA), 1.5% (w/w) penicillin-streptomycin (Gibco, Invitrogen USA), and 0.5% (w/w) fungizone (Gibco, Invitrogen USA). Cells were incubated at 37°C and 5% CO~2~.

Cytotoxic assay {#sec2-1}
---------------

The cytotoxic activity was measured by 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to obtain the value of the inhibitory concentration 50% (IC~50~) values. HeLa cells were distributed in the 96-well plates and seeded at the density of 10^4^ per well. The cells were grown for 24 hours in a humidified incubator at 37°C and 5% CO~2~. After seeding, the cells were treated with various serial concentrations of EPI. The tests were performed in concentrations of 250, 125, 62.5, 31.25, 15.625, 7.8125; and 3.906 μg/ml EPI. The cytotoxicity tests of doxorubicin were done in a series of 100, 50, 25, 12.5, 6.25, 3.125; and 1.56 μg/ ml. The cytotoxicity tests of cisplatin were done in a series of 200, 100, 50, 25, 12.5, 6.25, and 3.125 μg/ml. The absorbance of each well was measured using an ELISA reader (Bio-Rad) at λ 595 nm and converted to a percentage of viable cells. The percentage of viable cells was determined according to the following formula:
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This compound was combined with doxorubicin at concentrations of ½ IC~50~, 3/8 IC~50~, ¼ IC~50~, 1/8 IC~50~ to determine the potential use of the EPI compound as a co-chemotherapy agent for doxorubicin in HeLa cervical cancer cells. The same concentrations were used for the combination of EPI and CIS. Interpretations of the Combination Index (CI) values were based on [Table 1](#T1){ref-type="table"} (Chou, 2006).

###### 

The Measurement of Combination Index (CI)

  CI value   Interpretation
  ---------- -------------------------------
  \<0.1      very strong synergism
  0.1-0.3    strong synergism
  0.3-0.7    synergism
  0.7-0.9    moderate slight synergism
  0.9-1.1    nearly additive
  1.1-1.45   slight to moderate antagonism
  1.45-3.3   antagonism
  \>3.3      very strong antagonism effect

Analysis of drug synergy was performed by calculating the CI to measure the interaction between two drugs. The CI was calculated according to the median-effect principle of the Chou and Talalay method, using the CompuSyn software 1.4 (Chou, 2006).

ELISA {#sec2-2}
-----

HeLa cells were grown with the density of 10^6^ cells in the 6-well plates for 24 hours before treatment with EPI, DOX, CIS, or their combinations (EPI-DOX and EPI-CIS). Cells were treated for 24 hours and washed twice using PBS. The harvested cells were removed to conical tubes. Cells were harvested and counted, then centrifuged to precipitate cells, after adding a TEGM buffer solution which was a mixture of 10 mMTris-HCl, five mM EDTA, 10% glycerol, and 3 mMMgCl~2~, pH 6.8 with a 1 ml TEGM ratio. Next, the cells were homogenized at a moderate rate with a homogenizer (10 beats, top and bottom). The homogenate obtained was incubated at 4°C for 18 hours. Next, they were centrifuged at a rate of 1,000 × g for 20 min. The supernatant collected would be used for the measurement of the protein p53 (cat\#EH 3898 Fine Test, China) and TIMP3 (cat\#EH 0296) using the ELISA technique. The optical density of each well was determined using a microplate reader (Biorad). Concentrations were calculated per 1 million cells by the formula: protein concentration = \[concentration\] / cell number x 1 million cells.

qRT-PCR {#sec2-3}
-------

Total RNA was extracted from HeLa Cells samples using Qiagen miR-easy Mini Kit (cat \#217004) according to manufacturer's protocol. Synthesis of cDNA was following the protocol of QiagenmiScript II RT Kit (cat\#218161). MicroRNA expression was measured with the qRT-PCR method quantified by an Applied Biosystem 7500 FAST real-time PCR using Qiagen miScript SYBR Green PCR Kit cat\#218073). Appropriate internal control used Ctrl_miRTC_1 miScript Primer Assay (MS00000001) and primer for PCR Hsa-miR-34a (MS00003318), Universal primer were from Qiagen and used as directed. U6 was used as the host keeping gene, and the fold change in gene expression was calculated by the 2^-ΔΔCT^ method.

Statistics {#sec2-4}
----------

The expression of miR-34a, concentration of p53, and TIMP-3 protein were analyzed using one-way ANOVA and Post hoc test with Tukey test. The level of significance was set at p\<0.05.

Ethical issues {#sec2-5}
--------------

This research was approved by the ethical committee of the Faculty of Medicine, Public Health and Nursing, UniversitasGadjahMada, Yogyakarta (Ethical Clearance Number: KE/FK/0126/EC/2017).

Results {#sec1-3}
=======

Cytotoxicity Assessments of EPI, DOX, and CIS {#sec2-6}
---------------------------------------------

The cytotoxicity test on HeLa cells was performed in a 24-hour incubation time. The MTT result of the EPI compound showed that the IC~50~ value was 33.24 μg/ml, while the cytotoxicities of DOX and CIS against Hela cells were at the IC~50~ value of 4.8 μg/ml, and 23.34 μg/ml, respectively. The average IC~50~ values and the standard deviations of EPI, DOX, and CIS can be seen in [Figure 1](#F1){ref-type="fig"}.

![IC~50~ of EPI, DOX, and CIS](APJCP-19-2955-g002){#F1}

Combination Test of EPI with DOX using MTT {#sec2-7}
------------------------------------------

Synergistic effects of drug combinations were measured by the isobologram method to obtain the CIs. The dose-effect curve of the EPI, DOX, and its combination to the viability of HeLa cells are shown in [Figure 2A](#F2){ref-type="fig"}, while the CI values of EPI and DOX combinations are shown in [Figure 2B](#F2){ref-type="fig"}.

![Effect Curve of EPI and DOX on HeLa Cells (A). Normalized Isobologram for Combo, EPI-DOX (dose in μg/ml) (B).](APJCP-19-2955-g003){#F2}

Combination Test of EPI with CIS using MTT {#sec2-8}
------------------------------------------

The dose-effect curve of the EPI, CIS and its combination to the viability of HeLa cells are shown in [Figure 3A](#F3){ref-type="fig"}, while the CI value of EPI and CIS combination are shown in [Figure 3B](#F3){ref-type="fig"}.

![Effect Curve of EPI and CIS on HeLa Cells (A). Normalized Isobologram for Combo, EPI-CIS (dose in μg/ml) (B).](APJCP-19-2955-g004){#F3}

Measurement of the p53 protein expression with ELISA {#sec2-9}
----------------------------------------------------

Effect of EPI, DOX, CIS, and their combinations on p53 protein {#sec2-10}
--------------------------------------------------------------

The concentrations of p53 in the various groups are shown in [Figure 4A](#F4){ref-type="fig"}.

![Effect of EPI, DOX, CIS, and Their Combination on p53 of HeLa Cells (A). TIMP-3 of HeLa cells (B). MiR-34a of HeLa cells (C). a, Significantly different from Group 1; b, Significantly different from Group 5; c, Significantly different from Group 7 (p\<0.05).](APJCP-19-2955-g005){#F4}

The Elisa examination revealed that TIMP-3 levels were higher in groups 6, 7, and 8 compared to group 1, i.e. 1.67 ± 0.31 (6); 0.63 ± 0.11(7); 1.18 ± 0.18 (8). The result was statistically significant in groups 6, 7, and 8, p=0.00.

Effect of EPI, DOX, CIS, and their combinations on TIMP-3 protein {#sec2-11}
-----------------------------------------------------------------

The concentrations of TIMP-3 in the various groups are shown in [Figure 4B](#F4){ref-type="fig"}.

The Elisa examination revealed that TIMP-3 levels were higher in almost all treatment groups compared to group 1, i.e. 0.89 ± 0.09 (2); 0.80 ± 0.13 (4); 0.91 ± 0.37 (5); 3.81 ± 0.50 (6); 1.33 ± 0.14 (7); 2.93 ± 0.42 (8). The result was statistically significant in groups 6 and 8, p=0.00.

Effect of EPI, DOX, CIS, and their combinations to miR-34a expression {#sec2-12}
---------------------------------------------------------------------

The expressions of miR-34a on the various groups are shown in [Figure 4C](#F4){ref-type="fig"}.

The qRT-PCR examination revealed that miR-34a had significantly higher expression (p=0.00) in all treatment groups compared to group 1, i.e. 1.75 ± 0.01 (2); 3.18 ± 0.40 (3); 2.36 ± 0.43 (4); 8.76 ± 0.92 (5); 2.42 ± 0.40 (6); 1.44 ± 0.27 (7); 1.42 ± 0.09 (8).

Discussion {#sec1-4}
==========

The results of this study showed that the IC~50~ values of each tested single compound on HeLa cell line were 33.24 ± 3.01 μg/ml, 4.8 ± 0.10μg/ml, 23.34 ± 2.76 μg/ml for EPI, DOX, and CIS, respectively ([Figure 1](#F1){ref-type="fig"}). Based on the IC~50~ values, these results showed that EPI and CIS compounds were in a moderate category of anticancer activities, whereas DOX was categorized as having a potent anticancer activity against the HeLa cell line (Baharum et al., 2014; Caamal-Fuentes et al., 2015).

The EPI is an isoflavone compound synthesized from clove leaf oil. Its structure is like genistein and resembles 17β-Estradiol, which selectively binds to estrogen receptors (ER) with different affinity, and modulates recruitment of co-receptors and co-activators to influence the signaling of estrogen receptors (Hervouet et al., 2013). The chemical structure of the EPI compound is shown in [Figure 5B](#F5){ref-type="fig"}, while the genistein's structure is shown in [Figure 5A](#F5){ref-type="fig"}.

![Structure of Genistein (A), 1,2-Epoxy-3 (3-(3,4-dimetoxyphenyl)-4H-1-benzopyran-4-on) Propane](APJCP-19-2955-g006){#F5}

Genistein was reported to have many anticancer activities through several mechanisms such as antioxidant action, inhibiting tyrosine-specific protein kinases, and suppressing cell growth by stopping cell cycles. It is also known to induce apoptosis through multiple signaling pathways including Akt, NF-Kappa β, and Wnt signaling or by inhibition of angiogenesis (Huang et al., 2005; Li et al., 2011).

The structure of EPI in [Figure 5B](#F5){ref-type="fig"} shows the molecular structure of 3 rings with double bonds. The C2-C3 double bond significantly contributes to the molecular planarity and conjugation between the potent C and A/B rings as an anticancer agent (Wang et al., 2017). Previous studies demonstrated that the presence of C2-C3 double bonds was an important feature for inducing cytotoxicity in different cancer cells and for other pharmacological activities, such as colon adenocarcinoma (Murthy et al., 2012) and MDA-MB-231 breast cancer cells (Amrutha et al., 2014).

The addition of epoxy groups to the flavonoid skeletal framework of the EPI structure was thought to enhance the anticancer action, as in 4a, 5b-epoxy-germacra-1-(10), 11-(13)-dien-12,6a-olide which possesses anticancer properties through intrinsic pathway induction and extrinsic apoptosis in variable tumor cells through NF-Kappa β inhibition, p53 signaling activation, and regulation of Bcl-2 and ROS formation (Muhtasib et al., 2015).

The CI measurements of EPI-DOX were mostly below 0.1, indicating that the EPI compound has very strong synergism with DOX. The best combination with the 11% cancer cell viability was achieved at the combinations of ½IC~50~ of EPI and ½IC~50~ DOX. The CI test of the combination of EPI and CIS was between 0.7 and 0.9. This CI value indicates that the EPI-CIS combination has moderate slight synergism (Chou, 2006). The best combination with the cancer cell viability of 68% was achieved at the combinations of ½IC50 of EPI and ½IC~50~ CIS. Normalized isobologram for Combo EPI-DOX and EPI-CIS ([Figure 2B](#F2){ref-type="fig"} and [3B](#F3){ref-type="fig"}) showed that almost all combinations of EPI-DOX and EPI-CIS were located to the left of the curve. This result indicates that EPI had a synergistic effect with DOX and CIS. The findings of this study were similar to other studies showing that a combination of genistein with cisplatin could increase HeLa cell death by activating the NF-κB, Akt, and mTOR pathways (Sahin et al., 2012). Previous studies have shown that isoflavones such as genistein and daidzein synergized with many standard cancer drugs in many cancer cells such as pancreatic cancer and MCF-7 (Banerjee et al., 2007; Farjadian et al., 2015). Other studies shown that genistein is synergic with several standard drugs in several cancer cell cultures such as: prostate cancer cell culture (PC-3), pancreatic cancer (Bx PC-3), lung cancer cells (H460), and breast cancer cells (MDA- MB-231) (Li et al., 2005).Overexpression and activation of NF-κB could inhibit apoptotic response, and thereby reduce chemotherapeutic efficacy. The polyphenolic structure in genistein could alter this action, since genistein could decrease antiapoptotic protein Bcl-2 and Bcl-xL and down regulation NF-κB in pancreatic carcinoma cells (Lewandowska et al., 2014).

[Figure 4A](#F4){ref-type="fig"} shows that the concentrations of p53 in the groups treated with the combination of EPI-DOX and EPI-CIS were higher than the control group and the group treated with DOX and CIS alone (p\<0.05), while the group treated with EPI was not significantly different from the control group. This result contradicted a previous study which shown that genistein may trigger apoptosis by inhibiting APE1 redox activity, increasing p53 or inhibiting p53 degradation in A549 lung cancer cell culture (Zhu et al., 2015), and also inhibiting signal transduction of growth factors and other factors that can induce cell growth. The hydroxyl group-enriched structure of the flavonoid makes it more nucleophilic which could inhibit carcinogenesis (Cai and Han, 2015). Antitumor activity of genistein was associated with the down regulation of Akt, which serves as the major anti-apoptosis main pathway activated by EGFR. Akt pathways activate NF-κB through EBFR-independent resulting in the transcription of several genes, such as survive cyclooxygenase-2, Bcl-xL, and Bcl-2. These genes play a significant role at some stage in the cell cycle (cell growth, invasion, angiogenesis, and apoptosis). Genistein also activates p53, suppresses the expression of Bcl-2, increases the expression of Bax and Bak, and then activates the release of cytochrome c from mitochondria. The release of cytochrome c from mitochondria activates caspase 9, and this caspase activates caspase 3, 6, and 7, which in turn will induce apoptosis (Yeh et al., 2015).

[Figure 4B](#F4){ref-type="fig"} shows that in the CIS-treated group and in the combinations of EPI-DOX and EPI-CIS, the concentrations of TIMP-3 were higher than the control group. TIMP-3 concentrations in the groups treated with EPI-DOX and EPI-CIS were significantly higher than those treated with CIS alone (p\<0.05). Other studies also showed a combination of genistein and cisplatin were synergistic in human hepatocellular carcinoma (HCC) cells with a CI of 0.41. The anticancer mechanism of this combination involves inhibition of the increase in MMP-2 so as to inhibit metastasis (Chen et al., 2013). The expression of MMP-2 was inhibited by TIMP-3, allowing for a possible decrease in MMP-2 in the study through enhancement of TIMP-3.A recent study showed that 24 hour-treatment of genistein 100µM on HaCaT human cell lines increased the TIMP-3 concentration 2.6 times more than the negative control (Smolinska et al., 2018). All of these results suggest that the combinations of EPI-DOX and EPI-CIS might increase p53 and TIMP3 concentrations.

[Figure 4C](#F4){ref-type="fig"} shows the miR-34a expressions of all treatment groups were significantly higher than in the control group (p\<0.05), indicating that EPI, DOX, CIS, and its combinations might increase miR-34a expressions. While the highest miR-34a expression was in the DOX-treated group, this finding was consistent with a research on cancer animal model indicating that the expression of miR-34a increased in all concentrations of doxorubicin associated with cardiotoxicity (Ruggeri et al., 2018).

The miR-34a gene is located on chromosome 1p36.22 which is a region of frequent deletion and downregulation in many cancers (Henrich et al., 2012). There are two basic mechanisms that effect the regulation of expression of miR-34a which are activation by p53 and CpG island methylation. Oncoprotein E6 from HPV in uterine cervical cancer causes p53 deactivation which can cause downregulation of miR-34a. which then leads to an increase in proliferation and invasion (Zhang et al., 2016). Several previous studies have shown that polyphenols could increase the expression of miR-34a in breast cancer by down regulating Bcl-2 and Bmi-1 as targets (Guo et al., 2013). Luteolin which belongs to the flavonoid family could decrease Bcl-2 expression and induce apoptosis partly through upregulation of miR-34a expression in gastric cancer cells (Wu et al., 2015). The molecular mechanisms leading to miR-34a up regulation by polyphenol are poorly understood, but several lines of evidence suggest that epigenetic modification of promoters may be involved. In cancer, mutations or inactivation of the p53 and CpG methylation genes of miR-34a promoters will result in decreased expression of miRNA-34a (Chim et al., 2010; Hermeking, 2010; Siemens et al., 2013; Nindrea et al., 2017).

The highest p53 concentrations occurred in groups 6, 8, and 7, whereas the highest miR-34a expression occurred in groups 4, 5, and 6. This result did not correspond with the assumption above that high p53 concentrations activated miR-34a and thus increased the expression of miR-34a. This finding might be due to the complexity of the p53 relationship with miR-34a. In addition to p53 activating miR-34a, p53 is both an indirect and direct target of miR-34a. MiRNA-34a has several targets that influence the expression of p53, i.e., Silent Regulator Information 1 (SIRT1), a gene which functions for the deacetylation process of p53, so that the expression of miR-34a will inhibit the process of p53 deacylation. SIRT1, p53, and miR-34a form feedback loops inducing tumor suppression. SIRT1 can also inhibit miR-34a through histone deacetylation (Navarro and Lieberman, 2015; Okada et al., 2014;Yamakuchi and Lowenstein, 2009). Over expression of mouse double minute 2 homolog (MDM2), (Navarro and Lieberman, 2015; Pollutri et al., 2016), histone deacetylase 1 (HDAC1) (Bittremieux et al., 2016; Kaller et al., 2011), and the p53 transcription factor, Yin Yang 1, can induce downregulation of p53-signaling pathways. (Gronroos et al., 2004; Sui et al., 2004), resulting in increased expression of miR-34a. Inhibition of these genes will increase p53 expression, while p53 is a direct miR-34a target, and p53 mRNA was found to be highly enriched in the Bi-miR-34 pull-down (PD). According to one recent study, there was a decrease of p53 in 7 cell lines with high miR-34 expression (Navarro and Lieberman, 2015).

In conclusion, isoflavones from clove leaf oil (1,2-epoxy-3(3-(3,4-dimethoxyphenyl)-4H-1-benzopyran-4-on) propane (EPI) induced cell death in HeLa uterine cervix cancer cells and had a very synergistic co-chemotherapy effect with doxorubicin and was moderately synergistic with cisplatin. Combinations of (1,2-epoxy-3(3-(3,4-dimethoxyphenyl)-4H-1-benzopyran-4-on) propane with doxorubicin and cisplatin increased p53, TIMP-3, and miR-34a expressions in HeLa uterine cervix cancer cells.

There were two major limitations in this study. First, the study was conducted only on one type of cervical cancer cell culture (HeLa). Another limitation was the measurements of each parameter were only done once (posttest only) and not serialized, which led to this study not being able to describe the sequence or cascade of molecular changes in cancer cells due to the treatments. Future studies should focus on the other cervical cancer cell lines such as CaSki, Siha, and C33A and use in vivo assay tests in an animal model.
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